Country: Ինդոնեզիա
language: ինդոնեզերեն
source: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
CLONIDINE HYDROCHLORIDE
BOEHRINGER INGELHEIM INDONESIA - Indonesia
CLONIDINE HYDROCHLORIDE
75 MCG
TABLET
DUS, 2 PLASTIC BAG @ 15 KG (155.000-160.000 TABLET)
DELPHARM REIMS - France
2020-01-02
_1 _ CATAPRES ® Clonidine hydrochloride COMPOSITION 1 tablet contains 0.075 mg or 0.150 mg 2,6-dichloro-N-2-imidazolidinylidenebenzenamine hydrochloride (= clonidine hydrochloride) Excipients Tablets : Lactose monohydrate, calcium hydrogen phosphate anhydrous, maize starch dried, silica colloidal anhydrous, povidone, starch soluble, stearic acid INDICATIONS CATAPRES is indicated in the treatment of hypertension. CATAPRES may be employed alone or concomitantly with other antihypertensive agents. For the treatment of hypertensive crises, slow parenteral administration is especially suitable due to the rapid onset of action. _RENAL INSUFFICIENCY_ Dosage must be adjusted • according to the individual antihypertensive response which can show high variability in patients with renal insufficiency • according to the degree of renal impairment Careful monitoring is required. Since only a minimal amount of clonidine is removed during routine haemodialysis, there is no need to give supplemental clonidine following dialysis. CONTRAINDICATIONS CATAPRES should not be used in patients with known hypersensitivity to the active ingredient or other components of the product, and in patients with severe bradyarrhythmia resulting from either sick sinus syndrome or AV block of 2nd or 3rd degree. DOSAGE AND ADMINISTRATION Treatment of hypertension requires regular medical supervision. The dose of CATAPRES must be adjusted according to the patient's individual blood pressure response. TABLETS As an initial daily dose in mild to moderate forms of hypertension, 0.075 mg to 0.150 mg twice daily are sufficient in most cases. After a period of 2 - 4 weeks the dose may be increased if necessary until the desired response is achieved. Usually doses above 0.6 mg per day do not result in a further marked drop in blood pressure. In severe hypertension it might be necessary to increase the single dose further to 0.3 mg; this could be repeated up to three times daily (0.9 mg). Remarks: Black (Current CCDS 0067-03 – Safety Update); Blue (Lat read_full_document